PTO Rejects Gilead's Patents For HIV Drug
The U.S. Patent and Trademark Office has rejected Gilead Sciences Inc.'s four patents related to HIV/AIDS medication, finding that the company neglected to cite prior art when securing the patents....To view the full article, register now.
Already a subscriber? Click here to view full article